Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Coherus Oncology's Enterprise Value for the quarter that ended in Jun. 2026 was €137.18 Mil.
Coherus Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-130.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology EV-to-EBIT Related Terms
Coherus Oncology EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs NAUT, AVXL, SLNCF: EV-to-EBIT Comparison
For the Biotechnology subindustry, Coherus Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's EV-to-EBIT falls into.
Coherus Oncology's current Enterprise Value is €96.79 Mil.
Coherus Oncology's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-130.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a EV-to-EBIT of -0.74 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Coherus Oncology and its competitors. According to the industry distribution chart, Coherus Oncology ranks #999999 out of 370 companies in the Biotechnology industry.
Is Coherus Oncology's EV-to-EBIT too high?
Coherus Oncology's current EV-to-EBIT is -0.74. Based on the distribution chart, Coherus Oncology ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 63/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's EV-to-EBIT compare to NAUT and AVXL?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #999999 out of 370 companies for EV-to-EBIT. This places Coherus Oncology in the lower half of its industry. The industry median EV-to-EBIT is 16.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Coherus Oncology and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current EV-to-EBIT is -0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.92, compared to a current price of €1.02 — trading 11% above its estimated fair value. The current EV-to-EBIT is -0.74. Coherus Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current EV-to-EBIT is -0.74 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.02 is trading 11% above its estimated GF Value™ of €0.92.
GuruFocus considers Coherus Oncology to be Modestly Overvalued.
Key valuation signals for FRA:8C5:
EV-to-EBIT: -0.74
GF Value™: €0.92 vs. price of €1.02 (11% above fair value)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
63GF Score
Get the complete analysis for FRA:8C5
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
